Anida Pharma announces that FDA has granted orphan drug status to AP-001 for the treatment of neurotrophic keratopathy

by jonadmin | Jan 3, 2025 | Uncategorized

Cambridge, Massachusetts, January, 3, 2025 — Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for vision loss, today announced that the US Food and Drug Administration (F.D.A.) has granted Orphan Drug Designation...

Anida Pharma announces positive Pre-IND meeting with the FDA to set the path for clinical development of AP-001 for the treatment of retinopathy of prematurity

by jonadmin | Jun 4, 2024 | Uncategorized

Cambridge, Massachusetts, June, 04, 2024 — Anida Pharma, a biopharmaceutical company developing first-in-class treatments for vision loss, today announced the successful completion of a Type B pre-IND meeting with the US Food and Drug Administration (F.D.A.)....

Anida Pharma announces European Orphan Drug Designation for AP-001

by jonadmin | Jun 21, 2022 | Uncategorized

Cambridge, Massachusetts, June 21, 2022 — Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for the prevention and restoration of vision loss, today announced that the European Medicines Agency (EMA) has granted...

Anida Pharma granted rare pediatric disease designation for AP-001 for the prevention of retinopathy of prematurity (ROP)

by jonadmin | Sep 1, 2020 | Uncategorized

Cambridge, Massachusetts, March 31, 2020 — Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for the prevention and restoration of vision loss, today announced that the U.S. Food and Drug Administration (FDA) has...

Anida Pharma announces that FDA has granted AP-001 as a drug “for Rare Pediatric Disease” for the treatment of retinopathy of prematurity

by jonadmin | Aug 31, 2020 | Uncategorized

Cambridge, Massachusetts, August, 31, 2020 — Anida Pharma, a biopharmaceutical company developing ground-breaking treatments for vision loss, today announced that the US Food and Drug Administration (F.D.A.)  has granted rare pediatric disease designation to...

Anida Pharma announces US Orphan Drug Designation for AP-001

by jonadmin | Mar 31, 2020 | Uncategorized

Cambridge, Massachusetts, March 31, 2020 — Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for the prevention and restoration of vision loss, today announced that the U.S. Food and Drug Administration (FDA) has...